ISPOR Announces 2017-2018 Board of Directors

Published Jun 6, 2017
Princeton, NJ—June 6, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the election of the Society’s 2017-2018 Board of Directors. The new Board will assume office on July 1, 2017. The ISPOR Board of Directors are elected by its global membership. Shelby D. Reed, RPh, PhD assumes the role of president (2017-2018) after having served as the Society’s President-Elect. Dr. Reed is a professor at Duke University in Durham, NC, USA. Federico Augustovski, MD, MSc, PhD was elected to the position of president-elect (2017-2018). Dr. Augustovski is director of Health Economic Evaluations and Technology Assessment at the Institute for Clinical Effectiveness and Health Policy in Buenos Aires, Argentina. The following members were recently elected to the ISPOR Board of Directors for 3-year terms:
  • Meindert Boysen, PharmD, director for technology appraisal and highly-specialized technologies programs at the National Institute for Health and Care Excellence, London, England, UK
  • Stephanie R. Earnshaw, PhD, senior vice president, Health Economics at RTI Health Solutions, Raleigh-Durham, NC, USA
  • Jan Elias Hansen, PhD, vice president, Evidence for Access Unit, US Medical Affairs at Genentech, South San Francisco, CA, USA
Returning Board members include: Immediate Past President:
  • Lou Garrison, PhD, professor emeritus, Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy and adjunct professor, Departments of Global Health and Health Services at the University of Washington, Seattle, WA, USA
Treasurer:
  • Zeba M. Khan, RPh, PhD, vice president at Celgene Corporation, Summit, NJ, USA—reappointed to a second three-year term
CEO and Executive Director:
  • Nancy S. Berg, CEO and executive director at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA
Returning Board Members:
  • Joanna Lis, MSc, MBA, PhD,director, Market Access at Sanofi-Aventis, Warsaw, Poland
  • Gordon Liu, PhD, PKU Yangtze River Scholar professor of economics at Peking University National School of Development and director at PKU China Center for Health Economic Research, Beijing, China
  • Rosanna Tarricone, MSc, PhD,associate professor at Bocconi University, Milan, Italy
  • John Watkins, MPH, PharmD, formulary manager at Premera Blue Cross, Mountlake Terrace, WA, USA

###

  ABOUT ISPOR The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB  

Related Stories

How to Measure Meaningful Benefit for Patients With Rare Diseases

Oct 28, 2026

Value in Health announced the publication of a themed section examining new approaches to measuring meaningful change for patients with rare diseases.

ISPOR Launches Its First Interpretive Report on the HARPER Template

Oct 27, 2026

ISPOR launched its first Interpretive Report on the HARPER Protocol Template, which establishes shared expectations for how researchers should document and communicate the scientific decisions underlying their real-world evidence studies. ISPOR Interpretive Reports are designed to provide everyday language summaries of the Society's reports.

New Research and Policy Priorities Chart a Broader Role for HEOR

Oct 15, 2026

Value in Health announced today the publication of a new commentary that calls for expanding the role of health economics and outcomes research (HEOR) and increasing its impact on real-world decision making.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×